Psychotropic effects of antimicrobials and immune modulation by psychotropics: Implications for neuroimmune disorders

Neuropsychiatry

Volumn 2, Issue 4, 2012, Pages 331-343

  Obregon, Demian ^a   Parker Athill, Ellisa Carla ^a   Tan, Jun ^a   Murphy, Tanya ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CLAVULANIC ACID; CYCLOSERINE; CYTOKINE; GLUTAMATE TRANSPORTER; INTERLEUKIN 12; ISONIAZID DERIVATIVE; LINEZOLID; MACROLIDE; METABOTROPIC RECEPTOR 3; METHYLENE BLUE; MINOCYCLINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PENICILLIN DERIVATIVE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE DERIVATIVE; TOLL LIKE RECEPTOR 4; UNINDEXED DRUG; VANCOMYCIN;

ANTIDEPRESSANT ACTIVITY; ANTIMICROBIAL ACTIVITY; ATTENTION DEFICIT DISORDER; AUTISM; BLOOD BRAIN BARRIER; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INNATE IMMUNITY; INTESTINE FLORA; MAJOR DEPRESSION; MALARIA; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROPSYCHIATRY; NONHUMAN; OXIDATIVE STRESS; PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCAL INFECTION; PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTION; PRIORITY JOURNAL; PSYCHOTROPIC EFFECT; REVIEW; SCHIZOPHRENIA; TH1 CELL; TUBERCULOSIS; URINARY TRACT INFECTION;

EID: 84876511319     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.12.41     Document Type: Review

References (113)

1. Ganguli R, Yang Z, Shurin G et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 51(1), 1-10 (1994). (Pubitemid 24056866)
2. Careaga M, Van de Water J, Ashwood P. Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics 7(3), 283-292 (2010).
3. Muller N, Schwarz MJ. The immunemediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 12(11), 988-1000 (2007). Critical review of key mechanistic pathways implicated in the actions of both psychotropic and immunomodulatory antimicrobials. (Pubitemid 350006207)
4. Gabbay V, Coffey BJ, Guttman LE et al. A cytokine study in children and adolescents with Tourette's disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(6), 967-971 (2009).
5. Murphy TK, Sajid MW, Goodman WK. Immunology of obsessive-compulsive disorder. Psychiatry Clin. North Am. 29(2), 445-469 (2006).
6. Brimberg L, Benhar I, Mascaro-Blanco A et al. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology doi:10.1038/npp. 2012.56 (2012) (Epub ahead of print).
7. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 167(3), 261-280 (2010).
8. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat. Med. 9(7), 914-920 (2003). (Pubitemid 36889935)
9. Boulanger LM. Immune proteins in brain development and synaptic plasticity. Neuron 64(1), 93-109 (2009). Psychotropic effects of antimicrobials & immune modulation by psychotropics Review
10. Derecki NC, Privman E, Kipnis J. Rett syndrome and other autism spectrum disorders-brain diseases of immune malfunction? Mol. Psychiatry 15(4), 355-363 (2010). Comparison of genetic autism and other autism spectrum disorders from the perspective of immune dysregulation.
11. Battistini L, Piccio L, Rossi B et al. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 101(12), 4775-4782 (2003). (Pubitemid 36857734)
12. Bunevicius R, Prange AJ Jr. Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options. CNS Drugs 20(11), 897-909 (2006). (Pubitemid 44611139)
13. Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs 24(8), 655-667 (2010).
14. Pickles HG, Simmonds MA. Antagonism by penicillin of g-aminobutyric acid depolarizations at presynaptic sites in rat olfactory cortex and cuneate nucleus in vitro. Neuropharmacology 19(1), 35-38 (1980). (Pubitemid 10167116)
15. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 33(3), 729-736 (2007). (Pubitemid 47343710)
16. Hinze-Selch D, Daubener W, Eggert L, Erdag S, Stoltenberg R, Wilms S. A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence. Schizophr. Bull. 33(3), 782-788 (2007). (Pubitemid 47343717)
17. Bunevicius R, Velickiene D, Prange AJ Jr. Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves' disease. Gen. Hosp. Psychiatry 27(2), 133-139 (2005). (Pubitemid 40348778)
18. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman and Gilman's Pharmacological Basis of Therapeutics, 12th Edition. McGraw-Hill, NY, USA (2011).
19. Rothstein JD, Patel S, Regan MR et al. B-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433(7021), 73-77 (2005). (Pubitemid 40101145)
20. Snider LA, Lougee L, Slattery M, Grant P, Swedo SE. Antibiotic prophylaxis with azithromycin or penicillin for childhoodonset neuropsychiatric disorders. Biol. Psychiatry 57(7), 788-792 (2005). (Pubitemid 40487923)
21. Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol. Psychiatry 61(2), 250-252 (2007). (Pubitemid 46072785)
22. Kim DJ, King JA, Zuccarelli L et al. Clavulanic acid: a competitive inhibitor of b-lactamases with novel anxiolytic-like activity and minimal side effects. Pharmacol. Biochem. Behav. 93(2), 112-120 (2009).
23. Kost GC, Selvaraj S, Lee YB, Kim DJ, Ahn CH, Singh BB. Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking. Neurosci. Lett. 504(2), 170-175 (2011).
24. Palucha A, Tatarczynska E, Branski P et al. Group III mGlu receptor agonists produce anxiolytic-and antidepressant-like effects after central administration in rats. Neuropharmacology 46(2), 151-159 (2004). (Pubitemid 37532823)
25. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov. 4(12), 1015-1026 (2005).
26. Slusher BS, Vornov JJ, Thomas AG et al. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 5(12), 1396-1402 (1999). Key article describing a neuroprotective pathway exploited by certain antimicrobials.
27. Bacich DJ, Wozniak KM, Lu XC et al. Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J. Neurochem. 95(2), 314-323 (2005). (Pubitemid 41457500)
28. Thomas AG, Liu W, Olkowski JL et al. Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-b. Eur. J. Pharmacol. 430(1), 33-40 (2001). (Pubitemid 33042708)
29. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65(2), 232-260 (2001). (Pubitemid 32538179)
30. Semenkov Yu P, Makarov EM, Makhno VI, Kirillow SV. Kinetic aspects of tetracycline action on the acceptor (A) site of Escherichia coli ribosomes. FEBS Lett. 144(1), 125-129 (1982). (Pubitemid 13235627)
31. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with nonantimicrobial organ protective properties: possible mechanisms of action. Pharmacol. Res. 63(2), 102-107 (2011).
32. Paribello C, Tao L, Folino A et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 10, 91 (2010).
33. Siller SS, Broadie K. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis. Model Mech. 4(5), 673-685 (2011).
34. Agrawal SM, Lau L, Yong VW. MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 19(1), 42-51 (2008). (Pubitemid 350235982)
35. Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J. Neurosci. Res. 85(13), 2813-2823 (2007). (Pubitemid 47523564)
36. Levkovitz Y, Mendlovich S, Riwkes S et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 71(2), 138-149 (2010).
37. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 8(1), 131-145 (1995).
38. Tedla Y, Shibre T, Ali O et al. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiop. Med. J. 49(3), 211-220 (2011).
39. Winter C, Reutiman TJ, Folsom TD et al. Dopamine and serotonin levels following prenatal viral infection in mouse-implications for psychiatric disorders such as schizophrenia and autism. Eur. Neuropsychopharmacol. 18(10), 712-716 (2008).
40. Zink MC, Uhrlaub J, Dewitt J et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293(16), 2003-2011 (2005). (Pubitemid 40570894)
41. Dutta K, Basu A. Use of minocycline in viral infections. Ind. J. Med. Res. 133(5), 467-470 (2011).
42. Xiong L, Kloss P, Douthwaite S et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J. Bacteriol. 182(19), 5325-5331 (2000).
43. Provost JC, Funck-Brentano C, Rovei V, D'estanque J, Ego D, Jaillon P. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin. Pharmacol. Ther. 52(4), 384-393 (1992).
44. Cottagnoud P, Gerber CM, Acosta F, Cottagnoud M, Neftel K, Tauber MG. Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J. Antimicrobial. Chemother. 46(6), 981-985 (2000). (Pubitemid 32000609)
45. Mahesh R, Jindal A, Guatam B, Bhatt S, Pandey D. Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative - an investigation using behavioral tests battery of depression. Biochem. Biophys. Res. Commun. 409(4), 723-726 (2011).
46. Beck G, Brinkkoetter P, Hanusch C et al. Clinical review: immunomodulatory effects of dopamine in general inflammation. Crit. Care 8(6), 485-491 (2004). (Pubitemid 40073684)
47. Mori K, Ozaki E, Zhang B et al. Effects of norepinephrine on rat cultured microglial cells that express a1, a2, b1 and b2 adrenergic receptors. Neuropharmacology 43(6), 1026-1034 (2002). (Pubitemid 35341238)
48. Farber K, Pannasch U, Kettenmann H. Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell. Neurosci. 29(1), 128-138 (2005). (Pubitemid 40613058)
49. Sandler RH, Finegold SM, Bolte ER et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J. Child Neurol. 15(7), 429-435 (2000). (Pubitemid 30460223)
50. Finegold SM. State of the art; microbiology in health and disease. Intestinal bacterial flora in autism. Anaerobe 17(6), 367-368 (2011).
51. Weinstock LB. Antibiotic therapy may improve idiopathic restless legs syndrome: prospective, open-label pilot study of rifaximin, a nonsystemic antibiotic. Sleep Med. 11(4), 427 (2010).
52. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J. Antimicrob. Chemother. 31(Suppl. C), 1-9 (1993). (Pubitemid 23110695)
53. Jacobs MR, Johnson CE. Macrolide resistance: an increasing concern for treatment failure in children. Pediatr. Infect. Dis. J. 22(Suppl. 8), S131-S138 (2003). (Pubitemid 36999640)
54. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur. J. Clin. Pharmacol. 68(5), 479-503 (2011).
55. Colebunders R, Florence E. Neuropsychiatric reaction induced by clarithromycin. Sex Transm. Infect. 78(1), 75-76 (2002).
56. Richter SS, Heilmann KP, Beekmann SE et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin. Infect. Dis. 41(5), 599-608 (2005). (Pubitemid 41170346)
57. Guchev IA, Klochkov OI, Ivanitsa GV, Pervov IuA, Shturmina SM, Rosman SV. [Efficacy and safety of azithromycin prophylaxis of respiratory tract infections in military community]. Antibiot. Khimioter. 49(8-9), 34-35, 37-42 (2004).
58. Murphy BS, Sundareshan V, Cory TJ, Hayes D Jr, Anstead MI, Feola DJ. Azithromycin alters macrophage phenotype. J. Antimicrob. Chemother. 61(3), 554-560 (2008). (Pubitemid 351321127)
59. Morikawa K, Torii I, Morikawa S. Modulation of IgD and CD20 by ligation of CD5 on tonsillar B cells. Scand. J. Immunol. 55(1), 44-52 (2002). (Pubitemid 34227257)
60. Liadaki K, Petinaki E, Skoulakis C et al. Toll-like receptor 4 gene (TLR4), but not TLR2, polymorphisms modify the risk of tonsillar disease due to Streptococcus pyogenes and Haemophilus influenzae. Clin. Vaccin. Immunol. 18(2), 217-222 (2011).
61. Loof TG, Goldmann O, Medina E. Immune recognition of Streptococcus pyogenes by dendritic cells. Infect. Immun. 76(6), 2785-2792 (2008).
62. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2(4), 241-248 (1995). (Pubitemid 26082188)
63. Guttmann P, Ehrlich P. [The effect of methylene blue in malaria]. Berliner Klinische Wochenschrift 28, 953-956 (1891).
64. Adjalley SH, Johnston GL, Li T et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl Acad. Sci. USA 108(47), E1214-E1223 (2011).
65. Olson KR. California Poison Control System, Poisoning and Drug Overdose (5th Edition). Lange Medical Books/McGraw-Hill, NY, USA, xvi, 736 (2007).
66. Riedel W, Lang U, Oetjen U, Schlapp U, Shibata M. Inhibition of oxygen radical formation by methylene blue, aspirin, or α-lipoic acid, prevents bacteriallipopolysaccharide-induced fever. Mol. Cell Biochem. 247(1-2), 83-94 (2003). (Pubitemid 36798512)
67. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int. Clin. Psychopharmacol. 19(2), 89-95 (2004). (Pubitemid 38316767)
68. Prabakaran S, Swatton JE, Ryan MM et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9(7), 684-697, 643 (2004). (Pubitemid 38932173)
69. Verge B, Alonso Y, Valero J, Miralles C, Vilella E, Martorell L. Mitochondrial DNA (mtDNA) and schizophrenia. Eur. Psychiatry 26(1), 45-56 (2011).
70. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO-A) confirms a theoretical prediction. Br. J. Pharmacol. 152(6), 946-951 (2007). (Pubitemid 350100489)
71. Narsapur SL, Naylor GJ. Methylene blue. A possible treatment for manic depressive psychosis. J. Affect. Disord. 5(2), 155-161 (1983). (Pubitemid 13120409)
72. Naylor GJ, Smith AH, Connelly P. A controlled trial of methylene blue in severe depressive illness. Biol. Psychiatry 22(5), 657-659 (1987). (Pubitemid 17069852)
73. Eroglu L, Caglayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol. Res. 36(5), 381-385 (1997). (Pubitemid 28018061)
74. Kurihara TC, Orientomycin K. A new antibiotic. Ann. Rapt. Tohoku. Coll. Pharm. 3, 83-86 (1956).
75. Harris DA, Reagan MA, Wolf FJ, Peck RL, Wallick H, Woodruff HB. Discovery, development and and antimicrobial properties of d-amino-3- isoxazolidone (oxamycin), a new antibiotic produced by S. garyphalus n. sp. Antibiot. Chemother. 5, 183-190 (1955).
76. Otto MW, Basden SL, Leyro TM, Mchugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spect. 12(1), 51-56, 59-61 (2007).
77. Crane GE. Cyloserine as an antidepressant agent. Am. J. Psychiatry 115(11), 1025-1026 (1959). Important example of an antimicrobial compound with both immunomodulatory and psychotropic effects.
78. Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database Syst. Rev. 2, CD003153 (2002).
79. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebocontrolled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159(3), 480-482 (2002). (Pubitemid 34184748)
80. Muller N, Schwarz MJ. Neuroimmuneendocrine crosstalk in schizophrenia and mood disorders. Expert Rev. Neurotherapeut. 6(7), 1017-1038 (2006). (Pubitemid 44060296)
81. Meyer H, Mally J. [On hydrazine derivatives of pyridinecarboxylic acids.] Monatshefte Für Chem./Chem. Monthly 33(4), 393-414 (1912).
82. Kucharz EJ, Sierakowski SJ. Studies on immunomodulatory properties of isoniazid. I. Effect of isoniazid on mitogen-and anti-CD3 antibody-induced proliferation of human peripheral blood mononuclear cells and T cells. J. Hygiene Epidemiol. Microbiol. Immunol. 34(1), 99-105 (1990). (Pubitemid 20213018)
83. Kucharz EJ, Sierakowski SJ. Studies on immunomodulatory properties of isoniazid. III. Effect of isoniazid on proliferation of interleukin-dependent and interleukinindependent cell line. J. Hygiene Epidemiol. Microbiol. Immunol. 34(3), 305-308 (1990). (Pubitemid 20378741)
84. Kubera N, Lin AH, Kenis G, Bosmans E, Van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-g/interleukin-10 production ratio. J. Clin. Psychopharmacol. 21(2), 199-206 (2001). (Pubitemid 32221058)
85. O'Connell PJ, Wang X, Leon-Ponte M, Griffiths C, Pingle SC, Ahern GP. A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood 107(3), 1010-1017 (2006). Illustrative example of neurotransmitter signaling utilized for immune function. (Pubitemid 43156299)
86. Basterzi AD, Aydemir C, Kisa C et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 20(7), 473-476 (2005). (Pubitemid 41489458)
87. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Reimann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Archi. Psych. Clin. Neurosci. 247(4), 228-233 (1997). (Pubitemid 27399827)
88. Kubera M, Lin AH, Kenis G, Bosmans E, Van Bocksaele D, Maes M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-g/interleukin-10 production ratio. J. Clin. Psychopharmacol. 21(2), 199-206 (2001). (Pubitemid 32221058)
89. Xia Z, DePierre JW, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1b and TNF-a release in human blood monocytes and IL-2 and interferon-g in T cells. Immunopharmacology 34(1), 27-37 (1996). (Pubitemid 26284175)
90. Young MR, Matthews JP. Serotonin regulation of T-cell subpopulations and of macrophage accessory function. Immunology 84(1), 148-152 (1995).
91. Leon-Ponte M, Ahern GP, O'Connell PJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood 109(8), 3139-3146 (2007). (Pubitemid 46572497)
92. Abdel-Salam OM, Nofal SM, El-Shenawy SM. Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. Pharmacol. Res. 48(2), 157-165 (2003). (Pubitemid 36683164)
93. Abdel-Salam OM, Baiuomy AR, El-Batran S, Arbid MS. Evaluation of the antiinflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat. Pharmacol. Res. 49(2), 133-142 (2004). (Pubitemid 37492865)
94. Brustolim D, Ribeiro-Dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-a and interferon-g in mice. Int. Immunopharmacol. 6(6), 903-907 (2006).
95. Hashioka S, Klegeris A, Monji A et al. Antidepressants inhibit interferon-g-induced microglial production of IL-6 and nitric oxide. Exp. Neurol. 206(1), 33-42 (2007). (Pubitemid 46935120)
96. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344(13), 961-966 (2001). (Pubitemid 32240314)
97. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum. Psychopharmacol. 25(3), 201-215 (2010).
98. Murr C, Gerlach D, Widner B, Dierich MP, Fuchs D. Neopterin production and tryptophan degradation in humans infected by Streptococcus pyogenes. Med. Microbiol. Immunol. (Berl.) 189(3), 161-163 (2001). (Pubitemid 33726402)
99. Baune BT, Dannlowski U, Domschke K et al. The interleukin 1b (IL-1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol. Psychiatry 67(6), 543-549 (2010).
100. Yu YW, Chen TJ, Hong CJ, Chen HM, Tsai SJ. Association study of the interleukin-1b (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 28(6), 1182-1185 (2003).
101. Yoshida K, Alagbe O, Wang X et al. Promoter polymorphisms of the interferon-a receptor gene and development of interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 52(2), 55-61 (2005). (Pubitemid 41160320)
102. Pollmacher T, Schuld A, Kraus T, Haack M, Hinze-Selch D. On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr. Neurol. Psychiatry 69(Suppl. 2), S65-S74 (2001). (Pubitemid 32923850)
103. Muller N, Riedel M, Ackenheil M, Schwarz MJ. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J. Biol. Psychiatry 1(4), 173-179 (2000).
104. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9(11), 853-858 (1997). (Pubitemid 27494150)
105. Geiger H, Finkeistein BA. Largactil in the treatment of tuberculosis. Schweiz Med. Wochenschr. 84(37), 1063-1064 (1954).
106. Chedid L. Comparative action of promethazine, chlorpromazine and cortisone in mice receiving fatal doses of a bacterial endotoxin. C. R. Seances Soc. Biol. Fil. 148(11-12), 1039-1043 (1954).
107. Lind K, Kristiansen JE. Effect of some psychotropic drugs and a barbiturate on mycoplasmas. Int. J. Antimicrob. Agents 14(3), 235-238 (2000). (Pubitemid 30201550)
108. McNamee EN, Ryan KM, Griffin EW et al. Noradrenaline acting at central b-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration. Brain Behav. Immun. 24(4), 660-671 (2010).
109. van der Poll T, Jansen J, Endert E, Sauerwein HP, Van Deventer SJ. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect. Immun. 62(5), 2046-2050 (1994). (Pubitemid 24137012)
110. O'Sullivan JB, Ryan KM, Harkin A, Connor TJ. Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J. Neuroimmunol. 220(1-2), 34-42 (2010).
111. Borda T, Perez Rivera R, Joensen L, Gomez RM, Sterin-Borda L. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J. Immunol. 168(7), 3667-3674 (2002). (Pubitemid 34250439)
112. Borda T, Gomez R, Berria MI, Sterin-Borda L. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia 45(2), 144-154 (2004) (Pubitemid 38196991)
113. Antibiotic treatment trial for the PANDAS/PANS phenotype (AZT). NLM identifier: NCT01617083. http://clinicaltrials.gov/ct2/show/NCT01617083